Skip to content

Vaxcyte, Inc. PCVX Interest Income

Interest Income at other companies

Moderna logo
ModernaMRNA
$72M-20.0%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s interest income?
Vaxcyte, Inc. (PCVX) reported interest income of $26.61M in Q1 2026.
How has Vaxcyte, Inc.'s interest income changed year-over-year?
Vaxcyte, Inc.'s interest income decreased by 19.2% year-over-year, from $32.94M to $26.61M.
What is the long-term trend for Vaxcyte, Inc.'s interest income?
Over 4 years (2021 to 2025), Vaxcyte, Inc.'s interest income has grown at a 332.2% compound annual growth rate (CAGR), from $343K to $119.72M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.